Advertisement Hitachi receives FDA clearance for proton therapy system - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Hitachi receives FDA clearance for proton therapy system

Hitachi America, a subsidiary of Hitachi, has obtained FDA clearance for spot scanning irradiation technology of its Proton Beam therapy system for application at the MD Anderson Cancer Center in the US.

Proton Beam therapy is a new and remarkable type of cancer treatment that minimizes the unnecessary irradiation to the normal tissue compared with conventional electron beam and x-ray radiation therapy.

With this newly-developed technology, Hitachi expects to enhance its presence and position in the proton beam market in North America.